Results 51 to 60 of about 2,763 (183)
Cancer‐related pain: A bidirectional modulator of cancer progression
Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.CRP and tumour progression engage in a dynamic, bidirectional circuit mediated by multiple mechanisms involving neuroimmunology and cancer ‐neuroscience. Analgesic interventions may affect tumour progression, while anticancer therapies can influence pain. Targeting pain in cancer may have promising therapeutic value in cancer progression.
Junzhe He +5 more
wiley +1 more source
, 2020 Objective To assess the effectiveness, safety, and tolerability of erenumab in a real-life migraine population, while trying to identify responsiveness predictors.Background Erenumab is a fully human Ig-2 monoclonal antibody blocking the calcitonin gene ...
Cinzia Aurilia +29 more
core +1 more source
, 2023 Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown.
Jantzen F.T. (16473057) +3 more
core +1 more source
The Journal of Headache and Pain, 2020 Background erenumab was safe and effective in clinical trials for the prevention of migraine. However, real-life data are still lacking. Here we report the clinical experience from an Italian real-world setting using erenumab in patients with chronic ...
Antonio Russo +7 more
doaj +1 more source
Neurology and Therapy, 2023 Introduction Erenumab, a fully human monoclonal antibody against the calcitonin gene-related peptide receptor, is approved in Japan for the prevention of adult migraine.
Shigekazu Kitamura +8 more
doaj +1 more source
Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment
MedComm, Volume 7, Issue 9, September 2026.Migraine is a highly prevalent, female‐predominant, and disabling brain disorder shaped by genetic susceptibility, hormonal influences, modifiable attack factors, and comorbidity‐related progression. This review integrates current evidence on migraine epidemiology, phase‐specific neurovascular and neuroglial mechanisms, including CGRP signaling and ...
Weiwei Lu +9 more
wiley +1 more source
Migraine and Work‐Disability: New Treatments Reduce Work‐Related Burden Among Migraine Population
European Journal of Neurology, Volume 33, Issue 9, September 2026.Migraine is a disabling disease with a substantial hidden work‐related burden, often underestimated by standard patient‐reported outcome measures. In this study, patients treated with anti‐CGRP monoclonal antibodies showed a reduction in monthly migraine days and acute medication use, together with an improvement in work‐related burden as measured by ...
Danilo Antonio Montisano +14 more
wiley +1 more source
The Journal of Headache and Pain, 2022 Background Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre.
Michael Lowe +6 more
doaj +1 more source
European Journal of Neurology, Volume 33, Issue 9, September 2026.Cluster headache (CH) is a severe primary headache disorder and the neuropeptide calcitonin gene‐related peptide (CGRP) has been shown to be elevated ictally and interictally. We investigated tear fluid CGRP levels during experimental cluster headache attacks and showed elevated CGRP levels during these headache attacks.
Katharina Kamm +4 more
wiley +1 more source
Genetic ALS—Progressive Sleep Defects Precede the Onset of Clinical Disease
European Journal of Neurology, Volume 33, Issue 9, September 2026.Sleep disturbances in people carrying ALS‐causing gene mutations progressively worsen years before motor symptoms appear. These sleep abnormalities appear to progress regardless of how close individuals are to developing clinical ALS. Thus, polysomnography‐derived sleep measures could serve as sensitive, noninvasive biomarkers for tracking preclinical ...
Christina Lang +8 more
wiley +1 more source